Cancer Advisor

Interest in GLP-1 receptor agonists (GLP-1 RAs) such as Semaglutide, Tirzepatide, and Liraglutide has expanded far beyond diabetes and weight loss. Researchers are now exploring how these metabolic therapies may influence: cancer prevention, obesity-related cancer risk, tumor metabolism, inflammation, insulin signaling, and even response to immunotherapy. While GLP-1 drugs are not approved cancer treatments, mounting evidence suggests they may play a role in the future of metabolic precision oncology — particularly in cancers strongly linked to obesity, insulin resistance, and chronic inflammation. What Are GLP-1 Drugs? GLP-1 receptor agonists are medications originally developed for: type 2 diabetes, obesity, and metabolic disease. They work by: improving insulin sensitivity, reducing appetite, slowing gastric emptying, lowering blood glucose, and promoting substantial weight loss. Popular examples include: Ozempic Wegovy Mounjaro Zepbound Saxenda Their cancer relevance stems from th...

What Is Ferroptosis? Ferroptosis is a unique form of regulated cell death driven by iron-dependent lipid peroxidation — toxic oxidative damage to fats within cell membranes. Unlike apoptosis (“cell suicide”), ferroptosis causes cells to die through catastrophic oxidative membrane injury. Cancer researchers are increasingly interested in ferroptosis because many aggressive tumors appear vulnerable to it. The term “ferroptosis” was first introduced in 2012 by researchers at Columbia University. Why Ferroptosis Matters in Cancer Cancer cells often display biological features that make them susceptible to ferroptosis: Increased iron demand Elevated oxidative stress Altered metabolism Rapid membrane synthesis Dependence on antioxidant defenses These characteristics may create an “Achilles heel” that therapies can exploit. Tumor types believed to be especially ferroptosis-sensitive include: Pancreatic cancer Triple-negative breast cancer Glioblastoma Liver cancer Lung cancer Therapy-resista...

Cancer treatment is evolving faster than ever. From cutting-edge immunotherapies to AI-driven diagnostics, the discoveries of 2026 are reshaping how clinicians detect, monitor, and treat malignancies. These breakthroughs offer hope for longer survival, improved quality of life, and personalized therapies tailored to each patient. The 2026 American Association of Cancer Research (AACR) Annual Meeting took place in San Diego from April 17-22 and reflected how cancer research continues to evolve. Progress is increasingly driven by how advances across biology, technology, and policy come together to shape how we understand disease, develop new treatments, and bring them into practice. A central theme this year was the continued focus on cancer as more than just a collection of tumor cells. It is shaped by a complex ecosystem — immune cells, surrounding tissue, metabolism, and even the microbiome — all interacting in dynamic ways. Credit:  Statista 1. Immunotherapy: Expanding Beyond Che...

Modern oncology is rapidly evolving from a “one-size-fits-all” model into a far more individualized approach known as precision oncology. At the center of this transformation are: Genomics Nutrigenomics Biomarker testing Tumor sequencing AI-driven molecular analysis Precision nutrition Together, these fields are reshaping how clinicians understand cancer risk, treatment response, metabolism, inflammation, and even dietary interventions. The convergence of cancer genomics and personalized nutrition may become one of the defining themes of next-generation oncology. Genetics vs Genomics: Why the Difference Matters Many people use the terms “genetics” and “genomics” interchangeably, but they are not the same. ( Cancer.org ) Genetics Genetics focuses primarily on individual inherited genes passed down through families. Examples include: BRCA1 and BRCA2 mutations Lynch syndrome Familial adenomatous polyposis (FAP) These inherited mutations are often called germline mutations. They may increa...

Cancer is not just a genetic disease. It is also deeply influenced by metabolism, inflammation, immunity, hormones, blood vessel growth, and the tumor microenvironment. One of the most fascinating concepts in modern oncology is that tumors require a constant supply of nutrients and oxygen in order to grow. Without access to blood vessels and metabolic fuel, many tumors struggle to expand. This idea helped popularize the phrase: “Starving cancer cells.” But what does that actually mean scientifically? The answer lies in understanding: Tumor angiogenesis (blood vessel growth) Cancer metabolism Chronic inflammation Insulin and glucose signaling Immune system regulation Nutrient-sensing pathways Dietary considerations for a cancer patient can be viewed as catering to two mouths: one of the patient, governed by personal choices and the body’s metabolic responses to feeding or fasting; and the other of the tumor, which imposes its own demands.  A 2025 review in Nature  examines diet...

Key message: Lifestyle interventions do not replace immunotherapy — but they can meaningfully influence who responds, how well, and how long responses last by shaping metabolism, inflammation, and immune fitness. Why Lifestyle Matters in the Era of Immunotherapy Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4) have transformed cancer care, yet: Only 20–40% of patients achieve durable responses Many experience immune-related adverse events Metabolic and inflammatory status strongly influence outcomes Lifestyle factors act upstream of the immune system, affecting T-cell energetics, cytokine balance, gut microbiota, and systemic inflammation — all critical to immunotherapy success. Metabolic Health: The Primary Modifier of Immune Response Insulin Resistance and Hyperglycemia Poor glycemic control is associated with: Impaired T-cell activation Increased regulatory T-cell dominance Reduced response rates to checkpoint inhibitors Conversely, improved insulin sensitivity supports: CD8+ T-...

From “Undruggable” to One of the Most Important Targets in Cancer Medicine For decades, KRAS mutations were considered one of the most challenging problems in oncology. The protein was structurally smooth, biologically complex, and notoriously resistant to drug binding. It became known in medical literature as “undruggable.” That narrative changed dramatically in the early 2020s. Today, KRAS is no longer a scientific dead end—it is one of the most actively targeted oncogenic drivers in modern precision medicine. Multiple generations of KRAS inhibitors now exist, and treatment strategies are evolving from single-mutation targeting toward pan-RAS pathway control and combination therapy systems . However, despite major breakthroughs, KRAS-driven cancers remain difficult to cure. The reason is not a lack of drugs—but the adaptability of cancer biology itself. This article provides a complete 2026 update on KRAS inhibitors, including mechanisms, approved therapies, emerging drugs, resistanc...